- Home
- DSM vs AVIR Comparison
DSM vs AVIR Comparison
Compare DSM & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | AVIR |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DSM | AVIR |
|---|---|---|
| Price | $5.94 | $3.21 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 161.7K | ★ 362.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.69 | $2.46 |
| 52 Week High | $6.05 | $4.02 |
Technical Indicators
Market Signals| Indicator | DSM | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 55.28 |
| Support Level | $5.99 | $3.11 |
| Resistance Level | $6.09 | $3.23 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 44.44 | 79.85 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).